NIOSH has released an updated list of hazardous drugs for healthcare workers, incorporating 25 new drugs and removing seven.

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

TEVAN.UL] failed to convince a U.S. appeals court on Friday to reverse a decision that would remove patents related to its ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

Diabetes drug Victoza, or liraglutide, is a first generation GLP-1, a class of treatments that has seen overwhelming demand. It has been on the FDA’s shortage list since 2023, and currently ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

Neither drug is considered as effective as the brand ... requiring treatment for type 2 diabetes," Cody Stanford said. The list price for Ozempic and Mounjaro each run more than $1,000 a month ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming ...

From pig kidney transplants to the development of a new schizophrenia drug, here are five of the biggest medical ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.